What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer (NSCLC)? And what targeted agents does the NCCN recommend for these specific driver events?

What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer (NSCLC)? And what targeted agents does the NCCN recommend for these specific driver events?

What genomic alterations (i.e. driver events) does the NCCN identify for non-small cell lung cancer (NSCLC)? And what targeted agents does the NCCN recommend for these specific driver events?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Byoung Chul Cho, MD, PhD

Professor Byoung Chul Cho, MD, PhD

Yonsei Cancer Center
Yonsei University College of Medicine J
JE-UK Laboratory of Molecular Cancer Therapeutics
Seoul, Korea